Reference SummaryMelnick RL, Carcinogenesis 1999 May;20(5):867-78
Title |
Multiple organ carcinogenicity of inhaled chloroprene (2-chloro-1,3-butadiene) in F344/N rats and B6C3F1 mice and comparison of dose-response with 1,3-butadiene in mice. |
Authors |
Melnick RL; Sills RC; Portier CJ; Roycroft JH; Chou BJ; Grumbein SL; Miller RA |
Journal |
Carcinogenesis |
Volume |
20 |
Issue |
5 |
Year |
1999 |
Pages |
867-78 |
Abstract |
Chloroprene (2-chloro-1,3-butadiene) is a high production chemical used almost exclusively in the production of polychloroprene (neoprene) elastomer. Because of its structural similarity to 1,3-butadiene, a trans-species carcinogen, inhalation studies were performed with chloroprene to evaluate its carcinogenic potential in rats and mice. Groups of 50 male and female F344/N rats and 50 male and female B6C3F1 mice were exposed to 0, 12.8, 32 or 80 p.p.m. chloroprene (6 h/day, 5 days/week) for 2 years. Under these conditions, chloroprene was carcinogenic to the oral cavity, thyroid gland, lung, kidney and mammary gland of rats, and to the lung, circulatory system (hemangiomas and hemangiosarcomas), Harderian gland, kidney, forestomach, liver, mammary gland, skin, mesentery and Zymbal's gland of mice. Survival adjusted tumor rates in mice were fit to a Weibull model for estimation of the shape of the dose-response curves, estimation of ED10 values (the estimated exposure concentration associated with an increased cancer risk of 10%) and comparison of these parameters with those for 1,3-butadiene. Butadiene has been identified as a potent carcinogen in mice and has been associated with increased risk of lymphatic and hematopoietic cancer in exposed workers. Shape parameter values for most of the neoplastic effects of chloroprene and 1,3-butadiene were consistent with linear or supralinear responses in the area near the lowest tested exposures. The most potent carcinogenic effect of 1,3-butadiene was the induction of lung neoplasms in female mice, which had an ED10 value of 0.3 p.p.m. Since the ED10 value for that same response in chloroprene exposed mice was also 0.3 p.p.m., we conclude that the carcinogenic potency of chloroprene in mice is similar to that of 1,3-butadiene. Cancer potency of chloroprene is greater in the mouse lung than in the rat lung, but greater in the rat kidney than in the mouse kidney and nearly equivalent in the mammary gland of each species. |
Links |
J:54508 – MGI References 10334205 – National Library of Medicine/PubMed |
| Strain | Model Name | Treatment Agent(s) | Organ Affected | Frequency | Model Details |
|---|---|---|---|---|---|
| (C57BL/6 x C3H)F1 | Blood vessel hemangioma |
|
Blood vessel |
observed - 2 |
|
| (C57BL/6 x C3H)F1 | Blood vessel hemangioma |
|
Blood vessel |
observed |
|
| (C57BL/6 x C3H)F1 | Blood vessel hemangioma |
|
Blood vessel |
observed |
|
| (C57BL/6 x C3H)F1 | Blood vessel hemangiosarcoma |
|
(Unspecified organ) |
observed |
|
| (C57BL/6 x C3H)F1 | Blood vessel hemangiosarcoma |
|
Blood vessel |
observed - 2 |
|
| (C57BL/6 x C3H)F1 | Blood vessel hemangiosarcoma |
|
Liver |
4 |
|
| (C57BL/6 x C3H)F1 | Blood vessel hemangiosarcoma |
|
Blood vessel |
observed |
|
| (C57BL/6 x C3H)F1 | Blood vessel hemangiosarcoma |
|
Liver |
10 - 16.33 |
|
| (C57BL/6 x C3H)F1 | Blood vessel hemangiosarcoma |
|
Liver |
12 |
|
| (C57BL/6 x C3H)F1 | Blood vessel hemangiosarcoma |
|
Blood vessel |
observed |
|
| (C57BL/6 x C3H)F1 | Blood vessel neoplasm |
|
Blood vessel |
2 - 9 |
|
| (C57BL/6 x C3H)F1 | Blood vessel neoplasm |
|
Blood vessel |
12 - 45.2 |
|
| (C57BL/6 x C3H)F1 | Blood vessel neoplasm |
|
Blood vessel |
27.7 - 53.1 |
|
| (C57BL/6 x C3H)F1 | Blood vessel neoplasm |
|
Blood vessel |
16 |
|
| (C57BL/6 x C3H)F1 | Ear - Zymbal gland carcinoma |
|
Ear - Zymbal gland |
0 |
|
| (C57BL/6 x C3H)F1 | Ear - Zymbal gland carcinoma |
|
Ear - Zymbal gland |
0 |
|
| (C57BL/6 x C3H)F1 | Ear - Zymbal gland carcinoma |
|
Ear - Zymbal gland |
6 |
|
| (C57BL/6 x C3H)F1 | Eye - Harderian gland adenoma |
|
Eye - Harderian gland |
observed |
|
| (C57BL/6 x C3H)F1 | Eye - Harderian gland adenoma |
|
Eye - Harderian gland |
observed |
|
| (C57BL/6 x C3H)F1 | Eye - Harderian gland adenoma |
|
Eye - Harderian gland |
observed |
|
| (C57BL/6 x C3H)F1 | Eye - Harderian gland carcinoma |
|
Eye - Harderian gland |
observed |
|
| (C57BL/6 x C3H)F1 | Eye - Harderian gland carcinoma |
|
Eye - Harderian gland |
observed |
|
| (C57BL/6 x C3H)F1 | Eye - Harderian gland carcinoma |
|
Eye - Harderian gland |
observed |
|
| (C57BL/6 x C3H)F1 | Eye - Harderian gland neoplasm |
|
Eye - Harderian gland |
4 - 4.7 |
|
| (C57BL/6 x C3H)F1 | Eye - Harderian gland neoplasm |
|
Eye - Harderian gland |
10 - 32 |
|
| (C57BL/6 x C3H)F1 | Eye - Harderian gland neoplasm |
|
Eye - Harderian gland |
6 - 26.3 |
|
| (C57BL/6 x C3H)F1 | Forestomach hyperplasia - epithelial |
|
Forestomach |
8 |
|
| (C57BL/6 x C3H)F1 | Forestomach hyperplasia - epithelial |
|
Forestomach |
6 - 58 |
|
| (C57BL/6 x C3H)F1 | Forestomach hyperplasia - epithelial |
|
Forestomach |
16 |
|
| (C57BL/6 x C3H)F1 | Forestomach lesion |
|
Forestomach |
observed |
|
| (C57BL/6 x C3H)F1 | Forestomach lesion |
|
Forestomach |
observed |
|
| (C57BL/6 x C3H)F1 | Forestomach lesion |
|
Forestomach |
observed |
|
| (C57BL/6 x C3H)F1 | Forestomach squamous cell papilloma |
|
Forestomach |
0 - 2.4 |
|
| (C57BL/6 x C3H)F1 | Forestomach squamous cell papilloma |
|
Forestomach |
0 - 14.6 |
|
| (C57BL/6 x C3H)F1 | Forestomach squamous cell papilloma |
|
Forestomach |
0 |
|
| (C57BL/6 x C3H)F1 | Kidney - Renal tubule adenoma |
|
Kidney - Renal tubule |
0.2 |
|
| (C57BL/6 x C3H)F1 | Kidney - Renal tubule hyperplasia |
|
Kidney - Renal tubule |
4 |
|
| (C57BL/6 x C3H)F1 | Kidney - Renal tubule hyperplasia |
|
Kidney - Renal tubule |
33 - 34 |
|
| (C57BL/6 x C3H)F1 | Kidney - Renal tubule hyperplasia |
|
Kidney - Renal tubule |
36 |
|
| (C57BL/6 x C3H)F1 | Kidney - Renal tubule lesion |
|
Kidney - Renal tubule |
observed |
|
| (C57BL/6 x C3H)F1 | Kidney - Renal tubule lesion |
|
Kidney - Renal tubule |
observed |
|
| (C57BL/6 x C3H)F1 | Kidney - Renal tubule lesion |
|
Kidney - Renal tubule |
observed |
|
| (C57BL/6 x C3H)F1 | Kidney adenoma |
|
Kidney |
0 |
|
| (C57BL/6 x C3H)F1 | Kidney adenoma |
|
Kidney |
4.08 - 23.9 |
|
| (C57BL/6 x C3H)F1 | Kidney adenoma |
|
Kidney |
6 |
|
| (C57BL/6 x C3H)F1 | Liver - Bile duct hyperplasia |
|
Liver - Bile duct |
0 - observed |
|
| (C57BL/6 x C3H)F1 | Liver hepatocellular adenoma |
|
Liver |
observed |
|
| (C57BL/6 x C3H)F1 | Liver hepatocellular adenoma |
|
Liver |
observed |
|
| (C57BL/6 x C3H)F1 | Liver hepatocellular adenoma |
|
Liver |
observed |
|
| (C57BL/6 x C3H)F1 | Liver hepatocellular carcinoma |
|
Liver |
observed - 9 |
|
| (C57BL/6 x C3H)F1 | Liver hepatocellular carcinoma |
|
Liver |
observed - 28.4 |
|
| (C57BL/6 x C3H)F1 | Liver hepatocellular carcinoma |
|
Liver |
observed - 58.2 |
|
| (C57BL/6 x C3H)F1 | Liver neoplasm |
|
Liver |
40 - 86 |
|
| (C57BL/6 x C3H)F1 | Liver neoplasm |
|
Liver |
40 - 79.7 |
|
| (C57BL/6 x C3H)F1 | Liver neoplasm |
|
Liver |
60 - 84 |
|
| (C57BL/6 x C3H)F1 | Lung - Bronchiole hyperplasia |
|
Lung - Bronchiole |
0 |
|
| (C57BL/6 x C3H)F1 | Lung - Bronchiole hyperplasia |
|
Lung - Bronchiole |
20 - 46 |
|
| (C57BL/6 x C3H)F1 | Lung - Bronchiole hyperplasia |
|
Lung - Bronchiole |
31 - 60 |
|
| (C57BL/6 x C3H)F1 | Lung - Bronchiole lesion |
|
Lung - Bronchiole |
0 |
|
| (C57BL/6 x C3H)F1 | Lung - Bronchiole lesion |
|
Lung - Bronchiole |
observed |
|
| (C57BL/6 x C3H)F1 | Lung - Bronchiole lesion |
|
Lung - Bronchiole |
observed |
|
| (C57BL/6 x C3H)F1 | Lung adenoma |
|
Lung |
observed |
|
| (C57BL/6 x C3H)F1 | Lung adenoma |
|
Lung |
observed |
|
| (C57BL/6 x C3H)F1 | Lung adenoma |
|
Lung |
observed |
|
| (C57BL/6 x C3H)F1 | Lung carcinoma |
|
Lung |
4 - 14.1 |
|
| (C57BL/6 x C3H)F1 | Lung carcinoma |
|
Lung |
24 - 76 |
|
| (C57BL/6 x C3H)F1 | Lung carcinoma |
|
Lung |
28.3 - 56.9 |
|
| (C57BL/6 x C3H)F1 | Lung neoplasm |
|
Lung |
8 - 29.8 |
|
| (C57BL/6 x C3H)F1 | Lung neoplasm |
|
Lung |
56 - 92.9 |
|
| (C57BL/6 x C3H)F1 | Lung neoplasm |
|
Lung |
63.7 - 96.1 |
|
| (C57BL/6 x C3H)F1 | Mammary gland adenoacanthoma |
|
Mammary gland |
observed |
|
| (C57BL/6 x C3H)F1 | Mammary gland adenoacanthoma |
|
Mammary gland |
observed |
|
| (C57BL/6 x C3H)F1 | Mammary gland adenoacanthoma |
|
Mammary gland |
observed |
|
| (C57BL/6 x C3H)F1 | Mammary gland carcinoma |
|
Mammary gland |
observed |
|
| (C57BL/6 x C3H)F1 | Mammary gland carcinoma |
|
Mammary gland |
observed |
|
| (C57BL/6 x C3H)F1 | Mammary gland carcinoma |
|
Mammary gland |
observed |
|
| (C57BL/6 x C3H)F1 | Mammary gland neoplasm |
|
Mammary gland |
6 - 6.7 |
|
| (C57BL/6 x C3H)F1 | Mammary gland neoplasm |
|
Mammary gland |
10 - 42.5 |
|
| (C57BL/6 x C3H)F1 | Mammary gland neoplasm |
|
Mammary gland |
12.9 - 28 |
|
| (C57BL/6 x C3H)F1 | Mesodermal cell/mesoblast sarcoma |
|
Skin |
observed - 52.6 |
|
| (C57BL/6 x C3H)F1 | Mesodermal cell/mesoblast sarcoma |
|
Skin |
0 |
|
| (C57BL/6 x C3H)F1 | Mesodermal cell/mesoblast sarcoma |
|
Peritoneum - Mesentery |
0 |
|
| (C57BL/6 x C3H)F1 | Mesodermal cell/mesoblast sarcoma |
|
Skin |
22 - 39 |
|
| (C57BL/6 x C3H)F1 | Mesodermal cell/mesoblast sarcoma |
|
Peritoneum - Mesentery |
8 - 28.9 |
|
| (C57BL/6 x C3H)F1 | Mesodermal cell/mesoblast sarcoma |
|
Peritoneum - Mesentery |
6 - 11 |
|
| (C57BL/6 x C3H)F1 | Nose hyperplasia - adenomatous |
|
Nose |
4 - 6 |
|
| (C57BL/6 x C3H)F1 | Nose hyperplasia - adenomatous |
|
Nose |
0 - 96 |
|
| (C57BL/6 x C3H)F1 | Nose lesion - epithelial |
|
Nose |
observed |
|
| (C57BL/6 x C3H)F1 | Nose lesion - epithelial |
|
Nose |
observed |
|
| (C57BL/6 x C3H)F1 | Nose lesion - epithelial |
|
Nose |
observed |
|
| (C57BL/6 x C3H)F1 | Nose metaplasia |
|
Nose |
4 - 12 |
|
| (C57BL/6 x C3H)F1 | Nose metaplasia |
|
Nose |
2 - 98 |
|
| (C57BL/6 x C3H)F1 | Nose neoplasia - epithelial |
|
Nose |
0 |
|
| (C57BL/6 x C3H)F1 | Nose neoplasia - epithelial |
|
Nose |
0 |
|
| (C57BL/6 x C3H)F1 | Nose neoplasia - epithelial |
|
Nose |
0 |
|
| (C57BL/6 x C3H)F1 | (Unspecified organ) neoplasm |
|
(Unspecified organ) |
observed |